PLAA suppresses ovarian cancer metastasis via METTL3-mediated m6A modification of TRPC3 mRNA

Oncogene. 2022 Aug;41(35):4145-4158. doi: 10.1038/s41388-022-02411-w. Epub 2022 Jul 22.

Abstract

Wide metastasis contributes to a high death rate in ovarian cancer, and understanding of the molecular mechanism helps to find effective targets for metastatic ovarian cancer therapy. It has been found that phospholipase A2-activating protein (PLAA) is inactivated in some cancers, but its role in cancer metastasis remains unknown. Here, we found that PLAA was significantly downregulated in ovarian cancer highly metastatic cell lines and patients, and the low expression of PLAA was associated with poorer prognosis and high-risk clinicopathological features of patients. PLAA inhibited the migration and invasion of ovarian cancer cells and metastasis of transplanted tumor in the orthotopic xenograft mouse model. Meanwhile, PLAA inhibited metastasis of ovarian cancer by inhibiting transient receptor potential channel canonical 3 (TRPC3)-mediated the intracellular Ca2+ level. Mechanistically, PLAA inhibited methyltransferase-like 3 (METTL3) expression through the ubiquitin-mediated degradation, and METTL3 stabilized TRPC3 mRNA expression via N6-methyladenosine (m6A) modification. Our study verified the function and mechanism of the PLAA-METTL3-TRPC3 axis involved in ovarian cancer metastasis, with a view to providing a potential therapeutic approach for ovarian cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine
  • Animals
  • Carcinoma, Ovarian Epithelial
  • Female
  • Humans
  • Methyltransferases / metabolism*
  • Mice
  • Ovarian Neoplasms*
  • Proteins / metabolism*
  • RNA, Messenger
  • TRPC Cation Channels / genetics*
  • TRPC Cation Channels / metabolism

Substances

  • Proteins
  • RNA, Messenger
  • TRPC Cation Channels
  • TRPC3 cation channel
  • phospholipase A2-activating protein
  • Methyltransferases
  • Mettl3 protein, mouse
  • METTL3 protein, human
  • Adenosine